

Company Overview

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates. Monopar currently has three compounds in development: Validive® (clonidine MBT), a Phase 3-ready mucoadhesive buccal tablet for the prevention and treatment of radiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 2 clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced solid cancers.

Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020

Sep 14 2020, 8:30 AM EDT

Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19

Sep 9 2020, 8:30 AM EDT

Stock Overview

Symbol	MNPR
Exchange	Nasdaq
Market Cap	52.18m
Last Price	\$4.8601
52-Week	\$4.77 - \$48.00

10/19/2020 03:33 PM EDT

Management Team

Chandler D. Robinson, MD MBA MSc

Co-Founder, Chief Executive Officer and Board Member

Christopher M. Starr, PhD

Co-Founder and Executive Chairman of the Board

Andrew P. Mazar, PhD

Co-Founder and Executive Vice President, Research and Development

Chief Scientific Officer and Board Member

Kim R. Tsuchimoto

Chief Financial Officer, Secretary and Treasurer

Patrice Rioux, MD, PhD

Acting Chief Medical Officer

Monopar Therapeutics Inc.

1000 Skokie Blvd.

Suite 350

Wilmette, IL 60091

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.